280 related articles for article (PubMed ID: 34728374)
1. Repurposing antidepressants for anticancer drug discovery.
Song Y; Yang X; Yu B
Drug Discov Today; 2022 Jul; 27(7):1924-1935. PubMed ID: 34728374
[TBL] [Abstract][Full Text] [Related]
2. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
[TBL] [Abstract][Full Text] [Related]
3. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
4. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
[TBL] [Abstract][Full Text] [Related]
5. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing.
Li Z; Qin T; Li Z; Zhao X; Zhang X; Zhao T; Yang N; Miao J; Ma J; Zhang Z
Eur J Med Chem; 2021 Dec; 225():113778. PubMed ID: 34416665
[TBL] [Abstract][Full Text] [Related]
6. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors.
Li Z; Yuan Y; Wang P; Zhang Z; Ma H; Sun Y; Zhang X; Li X; Qiao Y; Zhang F; Su Y; Song J; Xie Z; Li L; Ma L; Ma J; Zhang Z
Eur J Med Chem; 2023 May; 253():115321. PubMed ID: 37037137
[TBL] [Abstract][Full Text] [Related]
8. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
[TBL] [Abstract][Full Text] [Related]
9. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
[TBL] [Abstract][Full Text] [Related]
11. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Effects of Tranylcypromine and NRF2 Inhibitor: A Repurposing Strategy for Effective Cancer Therapy.
Chen D; Chen S; Zhou F; Bo Chen L; Chen MW
ChemMedChem; 2023 Dec; 18(24):e202300282. PubMed ID: 37871186
[TBL] [Abstract][Full Text] [Related]
13. Repurposing Marketed Drugs as Antidepressants with In Silico, In Vivo, and In Vitro Screening Methods.
Naveena P; Usha KK; Swetha M; Hemalatha M; Swathi K
Adv Exp Med Biol; 2023; 1423():271-278. PubMed ID: 37525054
[TBL] [Abstract][Full Text] [Related]
14. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
[TBL] [Abstract][Full Text] [Related]
16. Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets.
Mottini C; Napolitano F; Li Z; Gao X; Cardone L
Semin Cancer Biol; 2021 Jan; 68():59-74. PubMed ID: 31562957
[TBL] [Abstract][Full Text] [Related]
17. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
19. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.
Vianello P; Botrugno OA; Cappa A; Dal Zuffo R; Dessanti P; Mai A; Marrocco B; Mattevi A; Meroni G; Minucci S; Stazi G; Thaler F; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
J Med Chem; 2016 Feb; 59(4):1501-17. PubMed ID: 26702542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
